S-1 was compared with paclitaxel when these agents were combined with carboplatin in patients with advanced NSCLC.
The data in Figure 3 show that for the combination with cisplatin and 5-FU, only OP dosage ≥ 600μg/mL reduced cell viability at 72h compared to monotherapy, while OP does not apparently affect the activity of either gemcitabine or paclitaxel, when compared to the cell viability after single chemo-drug treatment.
The data in Figure 3 show that for the combination with cisplatin and 5-FU, only OP dosage ≥ 600μg/mL reduced cell viability at 72h compared to monotherapy, while OP did not apparently affect the activity of either gemcitabine or paclitaxel, when compared to the cell viability after single chemo-drug treatment.
We also demonstrate a fourfold increase in efficacy of paclitaxel when delivered in the targeted nanoparticle systems, while significantly decreasing in vivo toxicity of the chemotherapy treatment.
In addition, isolated ovarian cancer stem cells exhibit much higher Bmi-1 levels compared to the differentiated or parental bulk tumor cells and have increased resistance to cisplatin and paclitaxel when compared to the tumor cells [23].
Given the bone marrow-sparing effects of paclitaxel when administered with carboplatin, either factor, the different dose and the separation of carboplatin and paclitaxel, could explain these discordant results.
The study aimed to analyze the pharmacokinetic profiles of sunitinib and paclitaxel when given in combination and to assess the tolerability and preliminary antitumor activity of the combination.
This overlap between the colchicine-binding site and the paclitaxel-binding site seems to explain the effect of paclitaxel when challenged by EBI, as seen in Table 1, 1 and may show a screening advantage for dual inhibitors.
To evaluate this possibility, the SEDDS formulations were dosed along with cyclosporine that further enhanced the bioavailability of paclitaxel when compared with Taxol®.
The aim of the present study was the analysis of the activity and toxicity of paclitaxel when given as second-line chemotherapy in NSCLC patients, in PF or secondary failure (SF) after first-line cisplatin-based chemotherapy.
